The Centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease

CNS Neuroscience and Therapeutics

Volumn 20, Issue 7, 2014, Pages 591-602

  Camilleri, Angelique ^a   Vassallo, Neville ^a  

^a UNIVERSITY OF MALTA   (Malta)

Author keywords

Mitochondria; Neuroprotection; Oxidative stress; Parkinson's disease; Therapeutics

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; CASPASE 3; CREATINE; CREATINE PHOSPHATE; CYTOCHROME C; DJ 1 PROTEIN; DOPAMINE TRANSPORTER; IDEBENONE; LEUCINE RICH REPEAT KINASE 2; MITOCHONDRIAL DNA; OXOGLUTARATE DEHYDROGENASE; PARKIN; POLYPHENOL; PROTEIN SERINE THREONINE KINASE; RASAGILINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIDECARENONE; URATE; ANTIOXIDANT;

CALCIUM HOMEOSTASIS; CITRIC ACID CYCLE; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ELECTRON TRANSPORT; GENE DUPLICATION; GENETIC DISORDER; HOMEOSTASIS; HUMAN; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL TARGETING SIGNAL; MITOCHONDRION; NERVE DEGENERATION; NERVE ENDING; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; POINT MUTATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; SUBSTANTIA NIGRA; TRANSIENT EXPRESSION; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; DOPAMINERGIC NEURONS; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84902535538     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12264     Document Type: Review

References (207)

1. Perier C, Vila M. Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med 2012;2:a009332.
2. Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson's disease: Features and pathophysiological mechanisms. Lancet Neurol 2009;8:1128-1139.
3. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008;7:97-109.
4. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 2000;80:315-360.
5. Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 2002;80:780-787.
6. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269.
7. Parker WD Jr., Parks JK, Swerdlow RH. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 2008;1189:215-218.
8. Winkler-Stuck K, Kirches E, Mawrin C, et al. Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson's disease. J Neural Transm 2005;112:499-518.
9. Singer TP, Ramsay RR, Ackrell BA. Deficiencies of NADH and succinate dehydrogenases in degenerative diseases and myopathies. Biochim Biophys Acta 1995;1271:211-219.
10. Sterky FH, Hoffman AF, Milenkovic D, et al. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum Mol Genet 2012;21:1078-1089.
11. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983;80:4546-4550.
12. Rojo AI, Montero C, Salazar M, et al. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci 2006;24:1874-1884.
13. Sherer TB, Richardson JR, Testa CM, et al. Mechanism of toxicity of pesticides acting at complex I: Relevance to environmental etiologies of Parkinson's disease. J Neurochem 2007;100:1469-1479.
14. +. Biochem Biophys Res Commun 1986;134:743-748.
15. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 1999;155:268-273.
16. Mizuno Y, Suzuki K, Sone N, Saitoh T. Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mouse brain in vivo. Neurosci Lett 1988;91:349-353.
17. Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 2005;134:57-66.
18. Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 2005;88:193-201.
19. Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors and Parkinson's disease: A case-control study in Taiwan. Neurology 1997;48:1583-1588.
20. Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. Pesticides and Parkinson's disease-is there a link? Environ Health Perspect 2006;114:156-164.
21. Gupta SP, Patel S, Yadav S, Singh AK, Singh S, Singh MP. Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: Is there any link with lipid peroxidation? Neurochem Res 2010;35:1206-1213.
22. Lambert AJ, Brand MD. Inhibitors of the quinone-binding site allow rapid superoxide production from mitochondrial NADH:Ubiquinone oxidoreductase (complex I). J Biol Chem 2004;279:39414-39420.
23. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011;119:866-872.
24. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.
25. Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002;136:317-324.
26. Hoglinger GU, Feger J, Prigent A, et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 2003;84:491-502.
27. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003;179:9-16.
28. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 2000;287:1265-1269.
29. Gash DM, Rutland K, Hudson NL, et al. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 2008;63:184-192.
30. Bringmann G, Feineis D, Bruckner R, et al. Bromal-derived tetrahydro-beta-carbolines as neurotoxic agents: Chemistry, impairment of the dopamine metabolism, and inhibitory effects on mitochondrial respiration. Bioorg Med Chem 2000;8:1467-1478.
31. Kochen W, Kohlmuller D, De Biasi P, Ramsay R. The endogeneous formation of highly chlorinated tetrahydro-beta-carbolines as a possible causative mechanism in idiopathic Parkinson's disease. Adv Exp Med Biol 2003;527:253-263.
32. Cheng F, Vivacqua G, Yu S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J Chem Neuroanat 2011;42:242-248.
33. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
34. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
35. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
36. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001;276:2380-2386.
37. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364:1167-1169.
38. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
39. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006;26:41-50.
40. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, Lee VM. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 2007;170:658-666.
41. Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010;486:235-239.
42. Choubey V, Safiulina D, Vaarmann A, et al. Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011;286:10814-10824.
43. Hsu LJ, Sagara Y, Arroyo A, et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157:401-410.
44. Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004;186:158-172.
45. Ellis CE, Murphy EJ, Mitchell DC, et al. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol 2005;25:10190-10201.
46. Klivenyi P, Siwek D, Gardian G, et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 2006;21:541-548.
47. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 2002;277:5411-5417.
48. Buttner S, Bitto A, Ring J, et al. Functional mitochondria are required for alpha-synuclein toxicity in aging yeast. J Biol Chem 2008;283:7554-7560.
49. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008;283:9089-9100.
50. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 2008;65:1272-1284.
51. Camilleri A, Zarb C, Caruana M, et al. Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim Biophys Acta 2013;1828:2532-2543.
52. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol 2009;41:2015-2024.
53. Kamp F, Exner N, Lutz AK, et al. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 2010;29:3571-3589.
54. Nakamura K, Nemani VM, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 2011;286:20710-20726.
55. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
56. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
57. Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-765.
58. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson's disease: Protein domains and functional insights. Trends Neurosci 2006;29:286-293.
59. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9:1231-1233.
60. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 2007;16:1319-1326.
61. Saha S, Guillily MD, Ferree A, et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 2009;29:9210-9218.
62. Biskup S, Moore DJ, Celsi F, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006;60:557-569.
63. Wang X, Yan MH, Fujioka H, et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 2012;21:1931-1944.
64. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-1567.
65. Farrer MJ. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-318.
66. Darios F, Corti O, Lucking CB, et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 2003;12:517-526.
67. Berger AK, Cortese GP, Amodeo KD, Weihofen A, Letai A, LaVoie MJ. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum Mol Genet 2009;18:4317-4328.
68. Stichel CC, Augustin M, Kuhn K, et al. Parkin expression in the adult mouse brain. Eur J Neurosci 2000;12:4181-4194.
69. Henn IH, Bouman L, Schlehe JS, et al. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci 2007;27:1868-1878.
70. Rothfuss O, Fischer H, Hasegawa T, et al. Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 2009;18:3832-3850.
71. Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004;279:18614-18622.
72. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 2003;100:4078-4083.
73. Pesah Y, Pham T, Burgess H, et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004;131:2183-2194.
74. Mortiboys H, Thomas KJ, Koopman WJ, et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 2008;64:555-565.
75. Muftuoglu M, Elibol B, Dalmizrak O, et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2004;19:544-548.
76. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 2009;5:706-708.
77. Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J Cell Biol 2010;189:671-679.
78. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304:1158-1160.
79. Wang HL, Chou AH, Yeh TH, et al. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis 2007;28:216-226.
80. Haque ME, Thomas KJ, D'Souza C, et al. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci U S A 2008;105:1716-1721.
81. Petit A, Kawarai T, Paitel E, et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 2005;280:34025-34032.
82. Pridgeon JW, Olzmann JA, Chin LS, Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 2007;5:e172.
83. Silvestri L, Caputo V, Bellacchio E, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005;14:3477-3492.
84. Wood-Kaczmar A, Gandhi S, Yao Z, et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE 2008;3:e2455.
85. Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A 2008;105:11364-11369.
86. Dagda RK, Cherra SJ 3rd, Kulich SM, Tandon A, Park D, Chu CT. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem 2009;284:13843-13855.
87. Gegg ME, Cooper JM, Schapira AH, Taanman JW. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS ONE 2009;4:e4756.
88. Wang HL, Chou AH, Wu AS, et al. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim Biophys Acta 2011;1812:674-684.
89. Tan JM, Dawson TM. Parkin blushed by PINK1. Neuron 2006;50:527-529.
90. Yang Y, Gehrke S, Imai Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A 2006;103:10793-10798.
91. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-259.
92. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004;5:213-218.
93. Krebiehl G, Ruckerbauer S, Burbulla LF, et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS ONE 2010;5:e9367.
94. Heo JY, Park JH, Kim SJ, et al. DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: Involvement of mitochondrial complex I assembly. PLoS ONE 2012;7:e32629.
95. Kim RH, Smith PD, Aleyasin H, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A 2005;102:5215-5220.
96. Yang W, Chen L, Ding Y, Zhuang X, Kang UJ. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum Mol Genet 2007;16:2900-2910.
97. Meulener M, Whitworth AJ, Armstrong-Gold CE, et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr Biol 2005;15:1572-1577.
98. Zhang L, Shimoji M, Thomas B, et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: Implications for pathogenesis. Hum Mol Genet 2005;14:2063-2073.
99. Canet-Aviles RM, Wilson MA, Miller DW, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 2004;101:9103-9108.
100. Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res 2009;87:123-129.
101. Lev N, Ickowicz D, Melamed E, Offen D. Oxidative insults induce DJ-1 upregulation and redistribution: Implications for neuroprotection. Neurotoxicology 2008;29:397-405.
102. Batelli S, Albani D, Rametta R, et al. DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: Relevance for Parkinson's disease and involvement of HSP70. PLoS ONE 2008;3:e1884.
103. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2004;2:e362.
104. Thomas KJ, McCoy MK, Blackinton J, et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 2011;20:40-50.
105. Gu G, Reyes PE, Golden GT, et al. Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol 2002;61:634-639.
106. Simon DK, Lin MT, Zheng L, et al. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging 2004;25:71-81.
107. Trimmer PA, Bennett JP Jr. The cybrid model of sporadic Parkinson's disease. Exp Neurol 2009;218:320-325.
108. Esteves AR, Lu J, Rodova M, et al. Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer. J Neurochem 2010;113:674-682.
109. Borland MK, Mohanakumar KP, Rubinstein JD, et al. Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim Biophys Acta 2009;1792:68-74.
110. Keeney PM, Quigley CK, Dunham LD, et al. Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 2009;20:897-907.
111. Ekstrand MI, Terzioglu M, Galter D, et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 2007;104:1325-1330.
112. Pickrell AM, Pinto M, Hida A, Moraes CT. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 2011;31:17649-17658.
113. Lohle M, Reichmann H. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci 2010;289:104-114.
114. Chaturvedi RK, Beal MF. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol Cell Neurosci 2013;55:101-114.
115. Burklen TS, Schlattner U, Homayouni R, et al. The creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits. J Biomed Biotechnol 2006;2006:35936.
116. Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med 2008;10:275-290.
117. Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci 2003;21:191-198.
118. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999;157:142-149.
119. + toxicity in an organotypic tissue culture system. Cell Transplant 2005;14:537-550.
120. Investigators NN-P. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.
121. Investigators NN-P. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 2008;31:141-150.
122. Elm JJ, Investigators NN-P. Design innovations and baseline findings in a long-term Parkinson's trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 2012;27:1513-1521.
123. Vassallo N. Polyphenols and health: New and recent advances. New York: Nova Science Publishers Inc, 2008.
124. Vassallo N, Scerri C. Mediterranean diet and dementia of the Alzheimer type. Curr Aging Sci 2013;6:150-162.
125. Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology 2012;78:1138-1145.
126. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010;15:7792-7814.
127. Stevenson DE, Hurst RD. Polyphenolic phytochemicals-just antioxidants or much more? Cell Mol Life Sci 2007;64:2900-2916.
128. Gazit E. A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J 2002;16:77-83.
129. Caruana M, Hogen T, Levin J, Hillmer A, Giese A, Vassallo N. Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 2011;585:1113-1120.
130. Blanchet J, Longpre F, Bureau G, et al. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1243-1250.
131. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001;78:1073-1082.
132. Li S, Pu XP. Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced mouse model of Parkinson's disease. Biol Pharm Bull 2011;34:1291-1296.
133. Liu LX, Chen WF, Xie JX, Wong MS. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci Res 2008;60:156-161.
134. Mu X, He GR, Yuan X, Li XX, Du GH. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice. Pharmacol Biochem Behav 2011;98:286-291.
135. Ortega-Arellano HF, Jimenez-Del-Rio M, Velez-Pardo C. Life span and locomotor activity modification by glucose and polyphenols in Drosophila melanogaster chronically exposed to oxidative stress-stimuli: Implications in Parkinson's disease. Neurochem Res 2011;36:1073-1086.
136. Long J, Gao H, Sun L, Liu J, Zhao-Wilson X. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson's disease model. Rejuvenation Res 2009;12:321-331.
137. Zhang K, Ma Z, Wang J, Xie A, Xie J. Myricetin attenuated MPP(+)-induced cytotoxicity by anti-oxidation and inhibition of MKK4 and JNK activation in MES23.5 cells. Neuropharmacology 2011;61:329-335.
138. Caruana M, Neuner J, Hogen T, et al. Polyphenolic compounds are novel protective agents against lipid membrane damage by alpha-synuclein aggregates in vitro. Biochim Biophys Acta 2012;1818:2502-2510.
139. 42 aggregates. J Alzheimers Dis 2011;27:767-779.
140. Odunze IN, Klaidman LK, Adams JD Jr. MPTP toxicity in the mouse brain and vitamin E. Neurosci Lett 1990;108:346-349.
141. Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 1997;104:469-481.
142. Yokota T, Igarashi K, Uchihara T, et al. Delayed-onset ataxia in mice lacking alpha -tocopherol transfer protein: Model for neuronal degeneration caused by chronic oxidative stress. Proc Natl Acad Sci U S A 2001;98:15185-15190.
143. Vatassery GT, DeMaster EG, Lai JC, Smith WE, Quach HT. Iron uncouples oxidative phosphorylation in brain mitochondria isolated from vitamin E-deficient rats. Biochim Biophys Acta 2004;1688:265-273.
144. Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 2005;134:109-118.
145. Gonzalez-Polo RA, Rodriguez-Martin A, Moran JM, Niso M, Soler G, Fuentes JM. Paraquat-induced apoptotic cell death in cerebellar granule cells. Brain Res 2004;1011:170-176.
146. Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 2002;59:1161-1169.
147. Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: A meta-analysis. Lancet Neurol 2005;4:362-365.
148. Fariss MW, Zhang JG. Vitamin E therapy in Parkinson's disease. Toxicology 2003;189:129-146.
149. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995;1271:195-204.
150. Moon Y, Lee KH, Park JH, Geum D, Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: Protective effect of coenzyme Q10. J Neurochem 2005;93:1199-1208.
151. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1, 2, 3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998;783:109-114.
152. Horvath TL, Diano S, Leranth C, et al. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology 2003;144:2757-2760.
153. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
154. Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007;64:938-944.
155. Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 2009;109:1427-1439.
156. Beal MF. Neuroprotective effects of creatine. Amino Acids 2011;40:1305-1313.
157. Mordente A, Martorana GE, Minotti G, Giardina B. Antioxidant properties of 2, 3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1, 4-benzoquinone (idebenone). Chem Res Toxicol 1998;11:54-63.
158. Parkinson MH, Schulz JB, Giunti P. Co-enzyme Q10 and idebenone use in Friedreich's ataxia. J Neurochem 2013;126(Suppl 1):125-141.
159. Tai KK, Pham L, Truong DD. Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Neurotox Res 2011;20:321-328.
160. Becker BF, Reinholz N, Ozcelik T, Leipert B, Gerlach E. Uric acid as radical scavenger and antioxidant in the heart. Pflugers Arch 1989;415:127-135.
161. Guerreiro S, Ponceau A, Toulorge D, et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: Potentiation by low-level depolarization. J Neurochem 2009;109:1118-1128.
162. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80:101-110.
163. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-567.
164. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-1468.
165. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008;167:831-838.
166. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: A prospective study. Lancet 2004;363:1277-1281.
167. Ramsay RR. Inhibitor design for monoamine oxidases. Curr Pharm Des 2013;19:2529-2539.
168. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
169. Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: A review of symptomatic and potential disease-modifying effects. CNS Drugs 2011;25:1061-1071.
170. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): Prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10:415-423.
171. Deftereos SN, Andronis CA. Discordant effects of rasagiline doses in Parkinson disease. Nat Rev Neurol 2010;6:1.
172. Binda C, Hubalek F, Li M, Edmondson DE, Mattevi A. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett 2004;564:225-228.
173. Jenner P, Langston JW. Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline. Mov Disord 2011;26:2316-2323.
174. Maruyama W, Akao Y, Youdim MB, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: Protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl 2000;60:171-186.
175. Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci 2001;939:320-329.
176. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes. Biochim Biophys Acta 2013. DOI: 10.1016/j.bbadis.2013.09.007.
177. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J Biol Chem 2001;276:4588-4596.
178. Lu C, Zhang D, Whiteman M, Armstrong JS. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA? Antioxid Redox Signal 2008;10:651-660.
179. Solesio ME, Prime TA, Logan A, et al. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease. Biochim Biophys Acta 2013;1832:174-182.
180. Ghosh A, Chandran K, Kalivendi SV, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med 2010;49:1674-1684.
181. Rodriguez-Cuenca S, Cocheme HM, Logan A, et al. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med 2010;48:161-172.
182. Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 2010;1201:96-103.
183. Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 2010;25:1670-1674.
184. Smith RA, Porteous CM, Coulter CV, Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 1999;263:709-716.
185. Trnka J, Blaikie FH, Smith RA, Murphy MP. A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radic Biol Med 2008;44:1406-1419.
186. Jauslin ML, Meier T, Smith RA, Murphy MP. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 2003;17:1972-1974.
187. Siler-Marsiglio KI, Pan Q, Paiva M, Madorsky I, Khurana NC, Heaton MB. Mitochondrially targeted vitamin E and vitamin E mitigate ethanol-mediated effects on cerebellar granule cell antioxidant defense systems. Brain Res 2005;1052:202-211.
188. Dhanasekaran A, Kotamraju S, Kalivendi SV, et al. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 2004;279:37575-37587.
189. Smith RA, Hartley RC, Murphy MP. Mitochondria-targeted small molecule therapeutics and probes. Antioxid Redox Signal 2011;15:3021-3038.
190. Mao G, Kraus GA, Kim I, et al. A mitochondria-targeted vitamin E derivative decreases hepatic oxidative stress and inhibits fat deposition in mice. J Nutr 2010;140:1425-1431.
191. Lim S, Rashid MA, Jang M, et al. Mitochondria-targeted antioxidants protect pancreatic beta-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity. Cell Physiol Biochem 2011;28:873-886.
192. Liang HL, Sedlic F, Bosnjak Z, Nilakantan V. SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery. Free Radic Biol Med 2010;49:1550-1560.
193. Zhelev Z, Bakalova R, Aoki I, Lazarova D, Saga T. Imaging of superoxide generation in the dopaminergic area of the brain in Parkinson's disease, using mito-TEMPO. ACS Chem Neurosci 2013;4:1439-1445.
194. Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 2006;8:E277-E283.
195. Szeto HH. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann N Y Acad Sci 2008;1147:112-121.
196. Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol 2005;70:1796-1806.
197. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004;279:34682-34690.
198. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal 2009;11:2095-2104.
199. Petri S, Kiaei M, Damiano M, et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2006;98:1141-1148.
200. 2+ in the regulation of cellular energetics. Biochemistry 2012;51:2959-2973.
201. +-induced cell death. J Neurochem 2013;125:473-485.
202. Melachroinou K, Xilouri M, Emmanouilidou E, et al. Deregulation of calcium homeostasis mediates secreted alpha-synuclein-induced neurotoxicity. Neurobiol Aging 2013;34:2853-2865.
203. Cali T, Ottolini D, Negro A, Brini M. Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics. Biochim Biophys Acta 2013;1832:495-508.
204. Cherra SJ 3rd, Steer E, Gusdon AM, Kiselyov K, Chu CT. Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol 2013;182:474-484.
205. Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ. Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 2008;14(Suppl 2):S112-S115.
206. Simuni T, Borushko E, Avram MJ, et al. Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study. Mov Disord 2010;25:2863-2866.
207. Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord 2013;28:1823-1831.